In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...

These biologics may have important safety benefits for older adults with higher infection risk compared to other existing treatments. Psoriasis ... of different treatment options for psoriatic ...

Biologics targeting IL-12, IL-23, or IL-17 are linked to lower infection risk in older adults with psoriatic disease compared to other systemic treatments. The study utilized Ontario's health ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Biologics ...

Opens in a new tab or window Until about 20 years ago, systemic treatment ... and biologic therapies remained in various stages of development. The most recent AAD/National Psoriasis Foundation ...

Treatment patterns in patients with moderate to severe psoriasis treated with biologics. . Poster presented at: 2025 AAD Annual Meeting; Orlando, FL; March 7-11, 2025.

Seeking treatment for depression ... and some experts believe biologic treatments for psoriasis may help prevent PsA from developing. While more work is needed to confirm this, ensuring everyone ...

BRIDGEWATER, N.J., and BENGALURU, India, March 7, 2025 /PRNewswire/ -- Biocon Biologics Ltd ... Ustekinumab in the treatment of moderate to severe chronic plaque psoriasis and by extension ...